Zynerba pharmaceuticals, inc. (ZYNE)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Cash flows from operating activities:
Net loss

-12,337

-10,714

-1,946

-11,135

-9,147

-7,790

-7,807

-12,007

-12,306

-8,118

-8,311

-8,323

-7,259

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-4,281

-

-3,993

-1,626

-1,491

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

41

35

36

32

29

26

25

21

26

25

24

23

20

22

25

13

13

13

8

3

1

Stock-based compensation

1,323

1,207

1,376

1,481

1,496

1,598

1,584

1,755

1,687

1,380

1,722

1,355

1,188

887

805

812

763

-

-

-

-

Changes in operating assets and liabilities:
Incentive and tax receivables

-1,135

1,166

8,579

779

643

349

-2,923

854

1,179

365

-2,810

1,418

1,395

1,332

588

982

352

-

-

-

-

Prepaid expenses and other assets

-767

-515

1,199

-1,022

-1,222

274

679

281

55

-590

664

77

172

45

16

409

-186

1,233

-376

-189

-307

Right-of-use assets

-1

-0

2

1

1

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred grant revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-7

-49

-199

-15

-14

Accounts payable

-1,535

1,373

-442

-210

-510

981

-2,799

1,670

1,250

338

1,031

973

-851

356

-1,189

1,691

185

-752

527

-233

995

Accrued expenses

-394

1,284

-226

2,741

-1,965

-228

504

779

216

-563

-420

-203

818

1,402

1,365

426

-1,182

2,113

92

489

-1,097

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-4,674

-

-

-

-

Net cash used in operating activities

-10,998

-7,464

-10,984

-6,848

-9,519

-6,207

-6,911

-8,916

-10,361

-6,713

-3,807

-7,671

-7,649

-

-

-

-

-3,194

-3,104

-1,572

-1,915

Cash flows from investing activities:
Purchases of property and equipment

138

48

56

0

24

129

39

100

17

24

12

9

68

22

58

0

28

40

129

40

6

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-28

-

-

-

-

Net cash used in investing activities

-138

-48

-56

0

-24

-129

-39

-100

-17

-24

-12

-9

-68

-

-

-

-

-40

-129

-40

-6

Cash flows from financing activities:
Proceeds from the issuance of common stock

1,816

90

-4

26,387

18,713

-

-

-

-

3,047

0

0

54,245

-

-

-

-

-

-

-

-

Payment of financing fees and expenses

104

-

-

-

633

-

-

-

-

-

-

-

-

-

-

-

-

-

-

20

33

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-4,703

-

-

-

-

Net cash provided by financing activities

1,711

28

-72

27,210

18,079

-

-

-

-

2,997

-107

367

54,245

-

-

-

-

-59

42,298

-20

-33

Net (decrease) increase in cash and cash equivalents

-9,424

-7,484

-11,113

20,362

8,535

-6,413

23,062

-9,016

-10,378

-3,741

-3,927

-7,313

46,527

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,293

39,063

-1,633

-1,954

Supplemental disclosures of cash flow information:
Deferred financing costs included in accounts payable and accrued expenses

57

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Property and equipment acquired unpaid at end of period

143

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in property and equipment acquired but not paid

-

-

-

-

-

-

-

-

-

-

-

-

-6

-

-

-

-

-

-

-

-

Reclassification of deferred rent liability to right-of-use assets upon adoption of ASC 842

-

0

0

0

12

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Right-of-use assets and lease liability recorded upon adoption of ASC 842

-

0

0

0

325

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred offering costs included in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,391